GSK Vaccine Is First Ever to Win US Clearance for RSV in Older Adults
- Vaccine is first ever to be cleared for RSV in older adults
- GSK shot one of four RSV drugs set for US approval this year
GSK Plc headquarters in London.
Photographer: Chris Ratcliffe/BloombergThis article is for subscribers only.
GSK Plc’s vaccine for respiratory syncytial virus won clearance from US regulators, giving the drugmaker an edge in its race against Pfizer Inc. as its product becomes the first shot approved to protect older adults from the lung disease.
The vaccine was authorized for people aged 60 and above by the US Food and Drug Administration, GSK said Wednesday. The UK drugmaker has touted the shot, called Arexvy to sound like RSV, as a potential blockbuster.